Prevalence and treatment of pediatric dyslipidemia
10.5124/jkma.2021.64.6.410
- Author:
Kyungchul SONG
1
;
Ho-Seong KIM
;
Hyun Wook CHAE
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
- Publication Type:Focused Issue of This Month
- From:Journal of the Korean Medical Association
2021;64(6):410-415
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
As dyslipidemia at a young age is a risk factor for cardiovascular disease in adulthood, the screening and management of dyslipidemia in children and adolescents might be an important health issue. This review deals with issues related to the prevalence, diagnosis, screening, and treatment of pediatric dyslipidemia.Current Concepts: In Korea, the prevalence of pediatric dyslipidemia was 19.7% between 2007 and 2009. Dyslipidemia was defined according to the guidelines of the Korean Society of Pediatric Endocrinology: total cholesterol ≥200 mg/dL, low-density lipoprotein cholesterol ≥130 mg/dL, triglycerides ≥130 mg/dL, high-density lipoprotein cholesterol <40 mg/dL, or non-high-density lipoprotein cholesterol ≥145 mg/dL.Discussion and Conclusion: We recommend universal screening tests for dyslipidemia at ages 9–11 years and 17–21 years. Diet and lifestyle modifications are essential in the treatment of dyslipidemia. In children aged ≥10 years with a poor response to lifestyle modification, drug therapy is recommended. Pediatric dyslipidemia should be diagnosed and treated properly to reduce adult cardiovascular diseases and improve quality of life in this age group.
